The agricultural product developer has doubled its overall equity funding, closing a round led by corporate venturing unit Monsanto Growth Ventures.
Monsanto Growth Ventures, the corporate venture capital arm of agribusiness Monsanto, co-led a $24m series C round for US-based plant bacteria product developer NewLeaf Symbiotics on Monday with private equity firm Otter Capital.
The round also featured venture capital firms Lewis & Clark Ventures, Rockport Capital and Pangaea Ventures, private equity fund manager Open Prairie Ventures and unnamed additional investors.
Founded in 2013, NewLeaf is developing plant bacteria products for use in areas such as seed treatments for crops like…
